Centessa Pharmaceuticals (CNTA) Insider Trading & Ownership $17.04 -1.15 (-6.32%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.59%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$6.81 M Get CNTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Centessa Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CNTA Insider Buying and Selling by Quarter Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Centessa Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/22/2024Saurabh SahaCEOSell1,671$18.24$30,479.04 11/20/2024Saurabh SahaCEOSell55,000$16.89$928,950.00 10/25/2024Gregory M WeinhoffInsiderSell11,742$15.38$180,591.96 10/23/2024Saurabh SahaCEOSell2,592$15.32$39,709.44 10/21/2024Saurabh SahaCEOSell22,205$15.80$350,839.00 9/25/2024Gregory M WeinhoffInsiderSell16,619$15.69$260,752.11 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/20/2024Saurabh SahaCEOSell55,000$16.53$909,150.00 9/10/2024Saurabh SahaCEOSell175,000$16.52$2,891,000.00 9/9/2024Gregory M WeinhoffInsiderSell25,000$15.00$375,000.00 8/22/2024Gregory M WeinhoffInsiderSell12,198$12.17$148,449.66 8/22/2024Saurabh SahaCEOSell506$12.23$6,188.38 8/20/2024Saurabh SahaCEOSell4,169$12.32$51,362.08 3/25/2024Karen M AndersonInsiderSell51,160$11.88$607,780.80 2/1/2024Harris RotmanSVPSell4,267$8.10$34,562.70 (Data available from 1/1/2013 forward) CNTA Insider Trading Activity - Frequently Asked Questions Who is on Centessa Pharmaceuticals's Insider Roster? The list of insiders at Centessa Pharmaceuticals includes Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman, and Tia L Bush. Learn more on insiders at CNTA. What percentage of Centessa Pharmaceuticals stock is owned by insiders? 11.59% of Centessa Pharmaceuticals stock is owned by insiders. Learn more on CNTA's insider holdings. Which Centessa Pharmaceuticals insiders have been selling company stock? The following insiders have sold CNTA shares in the last 24 months: Antoine Yver ($117,899.60), Gregory M Weinhoff ($964,793.73), Harris Rotman ($270,337.06), Karen M Anderson ($607,780.80), Saurabh Saha ($5,207,677.94), and Tia L Bush ($35,840.00). How much insider selling is happening at Centessa Pharmaceuticals? Insiders have sold a total of 512,283 Centessa Pharmaceuticals shares in the last 24 months for a total of $7,204,329.13 sold. Centessa Pharmaceuticals Key ExecutivesDr. Saurabh Saha M.D. (Age 48)Ph.D., CEO & Director Compensation: $1.04MDr. David M. Chao Ph.D. (Age 56)Chief Administrative Officer Compensation: $710.3kMr. John J. Crowley CPA (Age 50)CFO and Principal Financial & Accounting Officer Ms. Tia L. Bush (Age 53)Chief Technology & Quality Officer Ms. Kristen K. Sheppard Esq.J.D., Senior Vice President of Investor Relations & Corporate CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 43)General Counsel, Chief Compliance Officer & Corporate Secretary Ms. Karen M. Anderson (Age 56)Chief People Officer Dr. Gregory M. Weinhoff M.B.A. (Age 53)M.D., Chief Business Officer Compensation: $655kDr. Mario Alberto Accardi Ph.D.President of the Orexin ProgramMs. April DovholukSenior Vice President of Development Operations More Insider Trading Tools from MarketBeat Related Companies Scholar Rock Insider Transactions Aclaris Therapeutics Insider Transactions Ocugen Insider Transactions Repare Therapeutics Insider Transactions Seres Therapeutics Insider Transactions Ventyx Biosciences Insider Transactions Agenus Insider Transactions Elanco Animal Health Insider Transactions Blueprint Medicines Insider Transactions Lantheus Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:CNTA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
